Adverse events
| Adverse event . | Severe (n = 9) . | Nonsevere (n = 10) . | Overall (n = 19) . |
|---|---|---|---|
| Patients with at least 1 event | 6 (66.7%) | 7 (70.0%) | 13 (68.4%) |
| Eye disorders | 1 (11.1%) | 0 | 1 (5.3%) |
| Conjunctivitis, allergic | 1 (11.1%) | 0 | 1 (5.3%) |
| Gastrointestinal disorders | 1 (11.1%) | 2 (20.0%) | 3 (15.79%) |
| Dyspepsia | 1 (11.1%) | 0 | 1 (5.3%) |
| Gingival bleeding | 0 | 1 (10.0%) | 1 (5.3%) |
| Nausea | 1 (11.1%) | 0 | 1 (5.3%) |
| Toothache | 0 | 1 (10.0%) | 1 (5.3%) |
| General disorders and administration site conditions | 1 (11.1%) | 2 (20.0%) | 3 (15.79%) |
| Injection site bruising | 0 | 1 (10.0%) | 1 (5.3%) |
| Pyrexia | 1 (11.1%) | 1 (10.0%) | 2 (10.53%) |
| Infections and infestations | 1 (11.1%) | 1 (10.0%) | 2 (10.53%) |
| Conjunctivitis | 1 (11.1%) | 0 | 1 (5.3%) |
| Nasopharyngitis | 0 | 1 (10.0%) | 1 (5.3%) |
| Injury, poisoning, and procedural complications | 0 | 1 (10.0%) | 1 (5.3%) |
| Subcutaneous hematoma | 0 | 1 (10.0%) | 1 (5.3%) |
| Musculoskeletal and connective tissue disorders | 5 (55.6%) | 1 (10.0%) | 1 (5.3%) |
| Arthralgia | 1 (11.1%) | 0 | 1 (5.3%) |
| Hemarthrosis | 3 (33.3%) | 0 | 3 (15.79%) |
| Muscle hemorrhage | 1 (11.1%) | 0 | 1 (5.3%) |
| Pain in extremity | 1 (11.1%) | 1 (10.0%) | 2 (10.53%) |
| Soft tissue hemorrhage | 1 (11.1%) | 0 | 1 (5.3%) |
| Nervous system disorders | 2 (22.2%) | 0 | 2 (10.53%) |
| Headache | 2 (22.2%) | 0 | 2 (10.53%) |
| Psychiatric disorders | 1 (11.1%) | 0 | 1 (5.3%) |
| Sleep disorder | 1 (11.1%) | 0 | 1 (5.3%) |
| Respiratory, thoracic, and mediastinal disorders | 2 (22.2%) | 1 (10.0%) | 3 (15.79%) |
| Cough | 1 (11.1%) | 0 | 1 (5.3%) |
| Dysphonia | 1 (11.1%) | 0 | 1 (5.3%) |
| Epistaxis | 0 | 1 (10.0%) | 1 (5.3%) |
| Hemoptysis | 1 (11.1%) | 0 | 1 (5.3%) |
| Rhinitis, allergic | 1 (11.1%) | 0 | 1 (5.3%) |
| Skin and subcutaneous tissue disorders | 0 | 1 (10.0%) | 1 (5.3%) |
| Eczema | 0 | 1 (10.0%) | 1 (5.3%) |
| Vascular disorders | 1 (11.1%) | 1 (10.0%) | 2 (10.53%) |
| Hematoma | 0 | 1 (10.0%) | 1 (5.3%) |
| Hemorrhage | 1 (11.1%) | 0 | 1 (5.3%) |
| Adverse event . | Severe (n = 9) . | Nonsevere (n = 10) . | Overall (n = 19) . |
|---|---|---|---|
| Patients with at least 1 event | 6 (66.7%) | 7 (70.0%) | 13 (68.4%) |
| Eye disorders | 1 (11.1%) | 0 | 1 (5.3%) |
| Conjunctivitis, allergic | 1 (11.1%) | 0 | 1 (5.3%) |
| Gastrointestinal disorders | 1 (11.1%) | 2 (20.0%) | 3 (15.79%) |
| Dyspepsia | 1 (11.1%) | 0 | 1 (5.3%) |
| Gingival bleeding | 0 | 1 (10.0%) | 1 (5.3%) |
| Nausea | 1 (11.1%) | 0 | 1 (5.3%) |
| Toothache | 0 | 1 (10.0%) | 1 (5.3%) |
| General disorders and administration site conditions | 1 (11.1%) | 2 (20.0%) | 3 (15.79%) |
| Injection site bruising | 0 | 1 (10.0%) | 1 (5.3%) |
| Pyrexia | 1 (11.1%) | 1 (10.0%) | 2 (10.53%) |
| Infections and infestations | 1 (11.1%) | 1 (10.0%) | 2 (10.53%) |
| Conjunctivitis | 1 (11.1%) | 0 | 1 (5.3%) |
| Nasopharyngitis | 0 | 1 (10.0%) | 1 (5.3%) |
| Injury, poisoning, and procedural complications | 0 | 1 (10.0%) | 1 (5.3%) |
| Subcutaneous hematoma | 0 | 1 (10.0%) | 1 (5.3%) |
| Musculoskeletal and connective tissue disorders | 5 (55.6%) | 1 (10.0%) | 1 (5.3%) |
| Arthralgia | 1 (11.1%) | 0 | 1 (5.3%) |
| Hemarthrosis | 3 (33.3%) | 0 | 3 (15.79%) |
| Muscle hemorrhage | 1 (11.1%) | 0 | 1 (5.3%) |
| Pain in extremity | 1 (11.1%) | 1 (10.0%) | 2 (10.53%) |
| Soft tissue hemorrhage | 1 (11.1%) | 0 | 1 (5.3%) |
| Nervous system disorders | 2 (22.2%) | 0 | 2 (10.53%) |
| Headache | 2 (22.2%) | 0 | 2 (10.53%) |
| Psychiatric disorders | 1 (11.1%) | 0 | 1 (5.3%) |
| Sleep disorder | 1 (11.1%) | 0 | 1 (5.3%) |
| Respiratory, thoracic, and mediastinal disorders | 2 (22.2%) | 1 (10.0%) | 3 (15.79%) |
| Cough | 1 (11.1%) | 0 | 1 (5.3%) |
| Dysphonia | 1 (11.1%) | 0 | 1 (5.3%) |
| Epistaxis | 0 | 1 (10.0%) | 1 (5.3%) |
| Hemoptysis | 1 (11.1%) | 0 | 1 (5.3%) |
| Rhinitis, allergic | 1 (11.1%) | 0 | 1 (5.3%) |
| Skin and subcutaneous tissue disorders | 0 | 1 (10.0%) | 1 (5.3%) |
| Eczema | 0 | 1 (10.0%) | 1 (5.3%) |
| Vascular disorders | 1 (11.1%) | 1 (10.0%) | 2 (10.53%) |
| Hematoma | 0 | 1 (10.0%) | 1 (5.3%) |
| Hemorrhage | 1 (11.1%) | 0 | 1 (5.3%) |
All adverse events were mild or moderate. The first number is the number of patients who suffered an adverse event and the number in the parenthesis is the percentage of patients who suffered an event.